Deze pagina is automatisch vertaald en de nauwkeurigheid van de vertaling kan niet worden gegarandeerd. Raadpleeg de Engelse versie voor een brontekst.

Een studie om de PK-karakteristieken, veiligheid, verdraagbaarheid en immunogeniciteit van HLX15-SC te vergelijken met DARZALEX FASPRO® in combinatie met lenalidomide en dexamethason (Rd) bij transplantatie-ongeschikte patiënten met nieuw gediagnosticeerd multipel myeloom

21 september 2026 bijgewerkt door: Shanghai Henlius Biotech

Een gerandomiseerde, dubbelblinde, parallelgecontroleerde fase I-studie om de farmacokinetische kenmerken, veiligheid, verdraagbaarheid en immunogeniciteit van HLX15-SC te vergelijken met DARZALEX FASPRO® in combinatie met lenalidomide en dexamethason (Rd) bij transplantatie-ongeschikte patiënten met nieuw gediagnosticeerd multipel myeloom

The purpose of this study is to compare the pharmacokinetic (PK) similarity, safety, tolerability, immunogenicity, and efficacy of HLX15-SC versus US-DARZALEX FASPRO® following single and multiple subcutaneous (SC) injections in newly diagnosed MM patients ineligible for transplant.

Participants who meet all inclusion criteria and none of the exclusion criteria will receive either the HLX15-SC-Rd regimen or the D-Rd regimen for 4 cycles (one cycle = 4 weeks). After 4 cycles of treatment, based on clinical benefit and participant preference, participants may continue to receive the locally marketed daratumumab subcutaneous formulation (Dara-SC) in combination with Rd according to clinical practice, up to 32 weeks or until loss of clinical benefit, death, unacceptable toxicity, withdrawal of informed consent, or any other protocol-specified reason, whichever occurs first. After 32 weeks of dosing, participants will continue to receive appropriate standard of care according to local guidelines (including marketed Dara-SC).

Studie Overzicht

Toestand

Werving

Conditie

Interventie / Behandeling

Studietype

Ingrijpend

Inschrijving (Geschat)

258

Fase

  • Fase 1

Contacten en locaties

In dit gedeelte vindt u de contactgegevens van degenen die het onderzoek uitvoeren en informatie over waar dit onderzoek wordt uitgevoerd.

Studiecontact

Studie Locaties

  • Australië
      • Perth, Australië, 6005
        • Werving
        • Perth Blood Institute
  • China
    • Anhui
      • Bengbu, Anhui, China, 233000
        • Werving
        • The First Affiliated Hospital of Bengbu Medical University
      • Hefei, Anhui, China, 230601
        • Werving
        • The Second Affiliated Hospital of Anhui Medical University
      • Hefei, Anhui, China, 230031
        • Werving
        • Anhui Provincial Cancer Hospital
    • Beijing Municipality
      • Beijing, Beijing Municipality, China, 100191
        • Werving
        • Peking University Third Hospital
      • Beijing, Beijing Municipality, China, 100035
        • Werving
        • Peking University First Hospital
      • Beijing, Beijing Municipality, China, 100027
        • Werving
        • Beijing Chao-Yang Hospital Capital Medical University
    • Chongqing Municipality
      • Chongqing, Chongqing Municipality, China, 400016
        • Werving
        • The First Affiliated Hospital of Chongqing Medical University
    • Fujian
      • Fuzhou, Fujian, China, 350004
        • Werving
        • The First Affiliated Hospital of Fujian Medical University
      • Xiamen, Fujian, China, 361001
        • Werving
        • The First Affiliated Hospital of Xiamen University
    • Guangdong
      • Guangzhou, Guangdong, China, 510080
        • Werving
        • Guangdong General Hospital
      • Guangzhou, Guangdong, China, 510013
        • Werving
        • Guangzhou First People's Hospital
      • Guangzhou, Guangdong, China, 510220
        • Werving
        • Zhujiang Hospital of Southern Medical University
      • Meizhou, Guangdong, China, 514031
        • Werving
        • Meizhou People's Hospital
      • Shenzhen, Guangdong, China, 518020
        • Werving
        • Shenzhen People's Hospital
      • Shenzhen, Guangdong, China, 518036
        • Werving
        • Peking University Shenzhen Hospital
    • Guangxi
      • Liuzhou, Guangxi, China, 545007
        • Werving
        • Liuzhou Worker's Hospital
      • Nanning, Guangxi, China, 530213
        • Werving
        • Guangxi Medical University Cancer Hospital
    • Guizhou
      • Guiyang, Guizhou, China, 550004
        • Werving
        • The Affiliated Hospital of Guizhou Medical University
    • Hebei
      • Baoding, Hebei, China, 071030
        • Werving
        • Affiliated Hospital of Hebei University
      • Cangzhou, Hebei, China, 061000
        • Werving
        • Cangzhou People's Hospital
      • Shijiazhuang, Hebei, China, 050071
        • Werving
        • The Second Hospital of Hebei Medical Universit
      • Shijiazhuang, Hebei, China, 050052
        • Werving
        • Hebei medical university third hospital
    • Heilongjiang
      • Harbin, Heilongjiang, China, 150069
        • Werving
        • Harbin Medical University Cancer Hospital
    • Henan
      • Luoyang, Henan, China, 471003
        • Werving
        • The First Affiliated Hospital of Henan University of Science & Techinology
      • Xinxiang, Henan, China, 453000
        • Werving
        • Xinxiang Central Hospital
      • Zhengzhou, Henan, China, 450003
        • Werving
        • Henan Cancer Hospital
      • Zhengzhou, Henan, China, 450052
        • Werving
        • The First Affiliated Hospital of Zhengzhou University
      • Zhengzhou, Henan, China, 450003
        • Werving
        • Henan Provincial People's Hospital
    • Hubei
      • Wuhan, Hubei, China, 430071
        • Werving
        • Zhongnan Hospital of Wuhan University
      • Wuhan, Hubei, China, 430061
        • Werving
        • Renmin Hospital of Wuhan University
      • Wuhan, Hubei, China, 430014
        • Werving
        • Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
      • Wuhan, Hubei, China, 430030
        • Werving
        • Tongji Hospital Affiliated to Tongji Medical College of Huazhong University of Science & Technology
    • Hunan
      • Changsha, Hunan, China, 410011
        • Werving
        • The Second Xiangya Hospital of Central South University
      • Hengyang, Hunan, China, 421001
        • Werving
        • The First Affiliated Hospital Of University South China
    • Inner Mongolia
      • Hohhot, Inner Mongolia, China, 010030
        • Werving
        • The Affiliated Hospital of Inner Mongolia Medical University
    • Jangxi
      • Nanchang, Jangxi, China, 330008
        • Werving
        • The First Affiliated Hospital of Nanchang University
      • Nanchang, Jangxi, China, 330008
        • Werving
        • The second affiliated hospital of Nanchang University
    • Jiangsu
      • Nanjing, Jiangsu, China, 210009
        • Werving
        • Zhongda Hospital Southeast University
      • Nanjing, Jiangsu, China, 211166
        • Werving
        • Sir Run Run Hospital of Nanjing Medical University
      • Suzhou, Jiangsu, China, 215004
        • Werving
        • Nuclear Industry General Hospital (The Second Affiliated Hospital of Soochow University)
      • Wuxi, Jiangsu, China, 214000
        • Werving
        • Affiliated Hospital of Jiangnan University
      • Xuzhou, Jiangsu, China, 221006
        • Werving
        • The Affiliated Hospital of Xuzhou Medical University
    • Jiangxi
      • Ganzhou, Jiangxi, China, 341000
        • Werving
        • First Affiliated Hospital of Gannan Medical University
      • Nanchang, Jiangxi, China, 330029
        • Werving
        • Jiangxi Cancer Hospital
    • Liaoning
      • Dalian, Liaoning, China, 116001
        • Werving
        • Affiliated Zhongshan Hospital of Dalian University
      • Shenyang, Liaoning, China, 110004
        • Werving
        • Shengjing Hospital of China Medical University
      • Shenyang, Liaoning, China, 110001
        • Werving
        • The First Hospital of China Medical University
      • Shenyang, Liaoning, China, 110041
        • Werving
        • Liaoning Cancer Hospital & Institute
    • Shandong
      • Jinan, Shandong, China, 250022
        • Werving
        • Shandong Provincial Hospital
      • Jining, Shandong, China, 272000
        • Werving
        • Jining No.1 People's Hospital
      • Qingdao, Shandong, China, 266001
        • Werving
        • The Affiliated Hospital of Qingdao University
      • Weifang, Shandong, China, 261041
        • Werving
        • Weifang People's Hospital
    • Shanghai Municipality
      • Shanghai, Shanghai Municipality, China, 200032
        • Werving
        • Zhongshan Hospital, Fudan University
    • Shanxi
      • Taiyuan, Shanxi, China, 030001
        • Werving
        • The Second Hospital of Shanxi Medical University
      • Taiyuan, Shanxi, China, 030013
        • Werving
        • Shanxi Cancer Hospital
    • Sichuan
      • Chengdu, Sichuan, China, 610041
        • Werving
        • Sichuan Cancer Hospital
      • Chengdu, Sichuan, China, 610073
        • Werving
        • Sichuan Academy of Medical Sciences & Sichuan Provincial People's Hospital
    • Tianjin Municipality
      • Tianjin, Tianjin Municipality, China, 300060
        • Werving
        • Tianjin Medical University Cancer Institute & Hospital
      • Tianjin, Tianjin Municipality, China, 300308
        • Werving
        • Tianjin Cancer Hospital Airport Hospital
      • Tianjin, Tianjin Municipality, China, 300131
        • Werving
        • Tianjin People's Hospital
    • Zhejiang
      • Hangzhou, Zhejiang, China, 310006
        • Werving
        • Hangzhou First People's Hospital
      • Hangzhou, Zhejiang, China, 310015
        • Werving
        • Zhejiang Provincial People's Hospital
      • Hangzhou, Zhejiang, China, 310016
        • Werving
        • Sir Run Run Shaw Hospital Zhejiang University School of Medicine（The Grand Canal Campus）
      • Hangzhou, Zhejiang, China, 310020
        • Werving
        • The First Affiliated Hospital, Zhejiang University School of Medicine
      • Ningbo, Zhejiang, China, 315010
        • Werving
        • The First Affiliated Hospital of Ningbo University
      • Wenzhou, Zhejiang, China, 325000
        • Werving
        • The Second Affiliated Hospital of Wenzhou Medical University
  • Georgië
      • Tbilisi, Georgië, 0159
        • Nog niet aan het werven
        • JSC K. Eristavi National Center of Experimental and Clinical Surgery
      • Tbilisi, Georgië, 0160
        • Nog niet aan het werven
        • LLC Caucasus Medical Centre
  • Servië
      • Belgrade, Servië, 11080
        • Nog niet aan het werven
        • Clinical Hospital Centre Zemun
      • Kragujevac, Servië, 34000
        • Nog niet aan het werven
        • University Clinical Center Kragujevac
      • Niš, Servië, 8000
        • Nog niet aan het werven
        • University Clinical Center Nis
  • Verenigde Staten
    • Arkansas
      • Springdale, Arkansas, Verenigde Staten, 72762
        • Werving
        • Highlands Oncology Group, PA
    • Florida
      • Jacksonville, Florida, Verenigde Staten, 32256
        • Werving
        • Cancer Specialists of North Florida
      • Margate, Florida, Verenigde Staten, 33063
        • Werving
        • D&H National Research Center
      • Ocala, Florida, Verenigde Staten, 34474
        • Werving
        • Ocala Oncology Center
      • Plantation, Florida, Verenigde Staten, 33322
        • Werving
        • Florida Clinical Trials Group
      • Tamarac, Florida, Verenigde Staten, 33321
        • Werving
        • Florida Clinical Trials Group
    • Indiana
      • Dyer, Indiana, Verenigde Staten, 46311
        • Werving
        • Genesis Medical Research
    • Louisiana
      • Covington, Louisiana, Verenigde Staten, 70433
        • Werving
        • Pontchartrain Cancer Center
    • Texas
      • Houston, Texas, Verenigde Staten, 77030
        • Werving
        • Oncology Consultants (P1 Trials -Exigent Network)
      • Houston, Texas, Verenigde Staten, 77090
        • Werving
        • Lumi Research
    • Washington
      • Everett, Washington, Verenigde Staten, 98201
        • Werving
        • Optum Care Washington
      • Olympia, Washington, Verenigde Staten, 98506
        • Werving
        • American Oncology Network Vista Oncology Division / Physician partner associate

Deelname Criteria

Onderzoekers zoeken naar mensen die aan een bepaalde beschrijving voldoen, de zogenaamde geschiktheidscriteria. Enkele voorbeelden van deze criteria zijn iemands algemene gezondheidstoestand of eerdere behandelingen.

Geschiktheidscriteria

Leeftijden die in aanmerking komen voor studie

18 jaar en ouder (Volwassen, Oudere volwassene)

Accepteert gezonde vrijwilligers

Nee

Geslachten die in aanmerking komen voor studie

Allemaal

Beschrijving

Inclusion Criteria:

  1. Age ≥ 18 years at the time of signing the informed consent form (ICF).

  2. Body mass index (BMI): 18.5 kg/m2 ≤ BMI < 28 kg/m2.

  3. Subjects must participate voluntarily, understand the study, and sign the ICF.

  4. Patients must have a documented diagnosis of multiple myeloma (MM) according to the International Myeloma Working Group (IMWG) criteria, with measurable lesion .

  5. Serum albumin ≥ 35 g/L.

  6. Newly diagnosed, untreated, and considered ineligible for high-dose chemotherapy with autologous stem cell transplantation (ASCT) by the investigator.

  7. The patient's ECOG performance status must be 0 or 1 .

  8. Patient must have clinical laboratory values meeting the following criteria during the screening period:

    1. Hemoglobin ≥ 7.5 g/dL (≥ 5 mmol/L; red blood cell [RBC] transfusion or use of recombinant human erythropoietin at least 1 week prior to randomization is allowed).
    2. Absolute neutrophil count (ANC) ≥ 1.0 × 109/L (use of granulocyte-colony stimulating factor [G-CSF] is allowed).
    3. Alanine aminotransferase (ALT) ≤ 2.5 × upper limit of normal (ULN).
    4. Without the following evidence of impaired liver function, including mild impairment (total bilirubin ≤ ULN and AST > ULN or ULN < total bilirubin ≤ 1.5 x ULN), moderate impairment (1.5 x ULN < total bilirubin ≤ 3 x ULN), and severe impairment (total bilirubin > 3 x ULN).
    5. Measured creatinine clearance ≥ 40 mL/min .
    6. Corrected serum calcium < 14 mg/dL (< 3.5 mmol/L); or free ionized calcium < 6.5 mg/dL (< 1.6 mmol/L) .
    7. Platelet count ≥ 70 × 109/L for patients with plasma cells < 50% of bone marrow nucleated cells; platelet count > 50 × 109/L for all other patients (transfusion within 3 days prior to randomization to achieve the minimum platelet count is not permitted).

  9. Contraceptive criteria: Contraceptive use by men or women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.

    1. Female patients: a female patient is eligible to participate if she is not pregnant or breastfeeding, and at least one of the following conditions applies:

      Not a woman of childbearing potential (WOCBP) or WOCBP: must commit to either abstain continuously from heterosexual sexual intercourse or to use 2 methods of reliable birth control simultaneously from signed ICF to at least 140 days following the last dose of study products. This includes one highly effective contraceptive method with a failure rate of < 1% per year (tubal ligation, intrauterine device, hormonal [birth control pills, injections, hormonal patches, vaginal rings or implants] or partner's vasectomy) and one additional effective contraceptive method (male latex or synthetic condom, diaphragm, or cervical cap). Reliable contraception is indicated even where there has been a history of infertility, unless due to hysterectomy or bilateral oophorectomy.

      The subjects also need to agree not to donate or cryopreservation eggs (ova, oocytes) from signed ICF to at least 140 days following the last dose of study products.

    2. Male patients: male patients are eligible to participate if they agree to the following during the intervention period and for at least 140 days following the last dose of study products:

    Be abstinent from heterosexual intercourse as their preferred and usual lifestyle (abstinent on a long-term and persistent basis) and agree to remain abstinent.

    or Agree to use a male condom and female partner to use an additional highly effective contraceptive method with a failure rate of <1% per year as when having sexual intercourse with a woman of childbearing potential who is not currently pregnant.

    Agree not to donate or cryopreservation sperm.

  10. A WOCBP must have a negative serum pregnancy test at screening within 72 h prior to randomization. The investigator is responsible for review of medical history, menstrual history, and recent sexual activity to decrease the risk for inclusion of a woman with an early undetected pregnancy

Exclusion Criteria:

  1. Patient has a diagnosis of primary amyloidosis, monoclonal gammopathy of undetermined significance (MGUS), smoldering multiple myeloma (SMM), Waldenström's disease, or other conditions in which IgM M-protein is present in the absence of a clonal plasma cell infiltration with lytic bone lesions.

  2. Patient has plasma cell leukemia (according to IMWG criterion: ≥ 5% of plasma cells in the peripheral blood and/or an absolute plasma cell count of ≥ 2 x 109/L) or POEMS syndrome (polyneuropathy, organomegaly, endocrinopathy, monoclonal protein, and skin changes).

  3. Patient has prior or current systemic therapy or ASCT for MM, with the exception of an emergency use of a short course (equivalent of dexamethasone 40 mg/day for a maximum 4 days) of corticosteroids before randomization.

  4. Patient has peripheral neuropathy or neuropathic pain Grade 2 or higher, as defined by the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) Version 6.

  5. Patient has a history of malignancy (other than MM) within 3 years before the date of randomization (exceptions are squamous and basal cell carcinomas of the skin and carcinoma in situ of the cervix, or malignancy that in the opinion of the investigator is considered cured with minimal risk of recurrence within 3 years).

  6. Patient has clinical signs of meningeal involvement of MM.

  7. Patient has known chronic obstructive pulmonary disease (COPD) (defined as a forced expiratory volume in 1 second [FEV1] < 50% of predicted normal), persistent asthma, or a history of asthma within the last 2 years. Patient with known or suspected COPD or asthma must have a FEV1 test during screening.

  8. Patient is known to be seropositive for history of human immunodeficiency virus (HIV) or known to have treponema pallidum antibodies (Anti-TP).

  9. Patient is known to have active hepatitis B or C.

    1. Patient is seropositive for hepatitis B (defined by a positive test for hepatitis B surface antigen [HBsAg]). Patients with resolved infection (that is, patients who are HBsAg negative but positive for antibodies to hepatitis B core antigen [Anti-HBc] and/or antibodies to hepatitis B surface antigen [Anti-HBs]) must be screened using real-time polymerase chain reaction (PCR) measurement of hepatitis B virus (HBV) deoxyribonucleic acid (DNA) levels. Those who are PCR positive will be excluded.

      EXCEPTION: Patients with serologic findings suggestive of HBV vaccination (Anti-HBs positivity as the only serologic marker) AND a known history of prior HBV vaccination, do not need to be tested for HBV DNA by PCR.

    2. Patient is seropositive for hepatitis C must be screened using PCR measurement of hepatitis C virus (HCV) ribonucleic acid (RNA) levels. Those who are PCR positive will be excluded.

  10. Patient has any concurrent medical or psychiatric condition or disease (e.g., active systemic infection, uncontrolled diabetes, acute diffuse infiltrative pulmonary disease) that is likely to interfere with the study procedures or results, or that in the opinion of the investigator, would constitute a hazard for participating in this study.

  11. Patient has clinically significant cardiac disease, including:

    1. Myocardial infarction within 1 year before randomization, or an unstable or uncontrolled disease/condition related to or affecting cardiac function (e.g., unstable angina, congestive heart failure, New York Heart Association [NYHA] Class III-IV ).
    2. Cardiac arrhythmia (NCI-CTCAE Version 6 Grade ≥ 2) or clinically significant ECG abnormalities.
    3. Screening 12-lead ECG showing a baseline QT interval as corrected by Fridericia's formula (QTcF) (See Appendix 6) > 470 ms.

  12. Patient has known allergies, hypersensitivity, or intolerance to lenalidomide, corticosteroids, monoclonal antibodies or human proteins, or their excipients or known sensitivity to mammalian-derived products.

  13. Patient has history of drug abuse or substance abuse one year prior to randomization. Patient is known or suspected of not being able to comply with the study protocol (e.g., because of alcoholism, drug dependency, or psychological disorder).

  14. Patient is a woman who is pregnant, or breast-feeding, or planning to become pregnant or donate eggs (ova, oocytes) while enrolled in this study or within 140 days after the last dose of study products.

    Or patient is a man who plans to father a child and/or donate sperm while enrolled in this study or within 140 days after the last dose of study products.

    Patient does not agree to abstain completely from sexual intercourse, or plan to use a contraceptive method that is not acceptable to the investigator (unacceptable methods of contraception include: i. periodic abstinence [such as calendar method, ovulation method, basal body temperature method, post-ovulation safety period method, etc.], withdrawal, etc.; ii. medical contraceptive measures such as oral contraceptives, contraceptive injections, contraceptive patches, subcutaneous implantation, intrauterine hormone contraceptive devices, local contraceptives such as spermicides, etc.).

  15. Patient had radiation therapy within 14 days of randomization.

  16. Patient had plasmapheresis within 28 days of randomization.

  17. Patient had a history of blood donation or total blood loss of 200 mL or more within 3 months before randomization.

  18. Patient had major surgery within 28 days before randomization or has not fully recovered from surgery, or has surgery planned during the time the patient is expected to participate in the study or within 28 days after the last dose of study treatment. Kyphoplasty is not considered major surgery.

  19. Patient in clinical trials of any other drug or device within 3 months (or 5 half-lives of the corresponding investigational product if the half-life of the drug is long [5 half-lives > 3 months]) before randomization.

  20. Patient has any condition for which, in the opinion of the investigator, participation would not be in the best interest of the patient (e.g., compromise the well-being) or that could prevent, limit, or confound the protocol-specified assessments

Studie plan

Dit gedeelte bevat details van het studieplan, inclusief hoe de studie is opgezet en wat de studie meet.

Hoe is de studie opgezet?

Ontwerpdetails

  • Primair doel: Behandeling
  • Toewijzing: Gerandomiseerd
  • Interventioneel model: Parallelle opdracht
  • Masker: Verviervoudigen

Wapens en interventies

Deelnemersgroep / Arm
Interventie / Behandeling
Experimenteel: HLX15-SC-Rd

HLX15-SC-Rd
Geneesmiddel: HLX15-SC-Rd

Subjects will receive 1800 mg HLX15-SC via SC administration for up to 16 weeks: weekly during Week 1-8 (Cycle 1-2; 1 cycle = 4 weeks) and every two weeks during Week 9-16 (Cycle 3-4).
Actieve vergelijker: US-DARZALEX FASPRO®-Rd

US-DARZALEX FASPRO®-Rd
Geneesmiddel: US-DARZALEX FASPRO®-Rd

Subjects will receive 1800 mg US-DARZALEX FASPRO® via SC administration for up to 16 weeks: weekly during Week 1-8 (Cycle 1-2; 1 cycle = 4 weeks) and every two weeks during Week 9-16 (Cycle 3-4).

Wat meet het onderzoek?

Primaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
pharmacokinetic (PK) similarity
Tijdsspanne: 7 days

Area under the serum concentration-time curve from time 0 to day 7 (AUC0-7d) after the 1st dose.
7 days
pharmacokinetic (PK) similarity
Tijdsspanne: 7 days

The maximum (peak) serum drug concentration (Cmax) after the 1st dose.
7 days
pharmacokinetic (PK) similarity
Tijdsspanne: 16 weeks

Area under the serum concentration-time curve within a dosing interval at steady-state (AUCss) after the 12th dose
16 weeks
pharmacokinetic (PK) similarity
Tijdsspanne: 16 weeks

The maximum (peak) serum drug concentration at steady-state (Cmax,ss) after the 12th dose
16 weeks

Secundaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
PK characteristics
Tijdsspanne: 16 weeks

trough concentration (Ctrough)
16 weeks
PK characteristics
Tijdsspanne: 16 weeks

trough concentration at steady state (Ctrough,ss).
16 weeks
Safety: Adverse events (AEs), serious adverse events (SAEs), and adverse events of special interest (AESIs)
Tijdsspanne: 16 weeks

Adverse events (AEs), serious adverse events (SAEs), and adverse events of special interest (AESIs) terms and frequency of occurrence judged by investigators
16 weeks
Safety: Vital Signs
Tijdsspanne: 16 weeks

Vital Signs: including blood pressure (systolic and diastolic; mmHg) , pulse rate (beats/min) measured by hematomanometer
16 weeks
Safety: Vital Signs
Tijdsspanne: 16 weeks

including body temperature (°C) measured by clinical thermometer
16 weeks
Safety: Physical examinations
Tijdsspanne: 16 weeks

Physical examinations: includes general condition; head and neck; mucous membranes; chest; abdomen; spine; extremities; musculoskeletal system; neurological system; lymphatic system; and skin checked by investigators
16 weeks
Safety: Laboratory tests
Tijdsspanne: 16 weeks

Laboratory tests: include hematology, blood chemistry, and urinalysis measured by the department of medical laboratory in site
16 weeks
Safety: Electrocardiography
Tijdsspanne: 16 weeks

Electrocardiography: 12-lead ECG will be performed by qualified personnel using an ECG machine, includes heart rate（beats per minute ）
16 weeks
Safety: Electrocardiography
Tijdsspanne: 16 weeks

Electrocardiography: 12-lead ECG will be performed by qualified personnel using an ECG machine, includes PR interval（msec）.
16 weeks
Safety: Electrocardiography
Tijdsspanne: 16 weeks

Electrocardiography: 12-lead ECG will be performed by qualified personnel using an ECG machine, includes QRS duration (msec).
16 weeks
Safety: Electrocardiography
Tijdsspanne: 16 weeks

Electrocardiography: 12-lead ECG will be performed by qualified personnel using an ECG machine, includes QTc interval (msec).
16 weeks
Immunogenicity:
Tijdsspanne: 16 weeks

Incidence of anti-drug antibodies (ADA) and neutralizing antibodies (NAb) against the study products (HLX15-SC and US-DARZALEX FASPRO®) and hyaluronidase.
16 weeks
Efficacy:ORR
Tijdsspanne: 16 weeks

Investigator-assessed overall response rate (ORR): is defined as the percentage of all patients achieving a PR or better after the randomization date.
16 weeks
Efficacy: partial response (PR) rate
Tijdsspanne: 16 weeks

Partial response (PR) rate is defined as the percentage of all patients achieving a PR at any time point after the randomization date
16 weeks
Efficacy: very good partial response (VGPR) rate
Tijdsspanne: 16 weeks

Very good partial response (VGPR) rate is defined as the percentage of all patients achieving a VGPR at any time point after the randomization date.
16 weeks
Efficacy: complete response (CR) rate
Tijdsspanne: 16 weeks

Complete response (CR) rate is defined as the percentage of all patients achieving a CR at any time point after the randomization date.
16 weeks
Efficacy: stringent complete response (sCR) rate
Tijdsspanne: 16 weeks

Stringent complete response (sCR) rate is defined as the percentage of all patients achieving an sCR at any time point after the randomization date.
16 weeks
Efficacy: time to response
Tijdsspanne: 16 weeks

Time to Response (TTR) is defined as the time from randomization to the first documented response of PR or better. TTR will be analyzed only for patients who achieve a response of PR or better.
16 weeks

Medewerkers en onderzoekers

Hier vindt u mensen en organisaties die betrokken zijn bij dit onderzoek.

Sponsor

Shanghai Henlius Biotech

Studie record data

Deze datums volgen de voortgang van het onderzoeksdossier en de samenvatting van de ingediende resultaten bij ClinicalTrials.gov. Studieverslagen en gerapporteerde resultaten worden beoordeeld door de National Library of Medicine (NLM) om er zeker van te zijn dat ze voldoen aan specifieke kwaliteitscontrolenormen voordat ze op de openbare website worden geplaatst.

Bestudeer belangrijke data

Studie start (Werkelijk)

25 mei 2026

Primaire voltooiing (Geschat)

25 mei 2027

Studie voltooiing (Geschat)

22 februari 2028

Studieregistratiedata

Eerst ingediend

27 februari 2026

Eerst ingediend dat voldeed aan de QC-criteria

12 maart 2026

Eerst geplaatst (Werkelijk)

17 maart 2026

Updates van studierecords

Laatste update geplaatst (Werkelijk)

24 september 2026

Laatste update ingediend die voldeed aan QC-criteria

21 september 2026

Laatst geverifieerd

1 september 2026

Meer informatie

Termen gerelateerd aan deze studie

Trefwoorden

Aanvullende relevante MeSH-voorwaarden

Andere studie-ID-nummers

  • HLX15-SC-NDMM-001

Plan Individuele Deelnemersgegevens (IPD)

Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?

NEE

Informatie over medicijnen en apparaten, studiedocumenten

Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel

Ja

Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct

Nee

Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .

Abonneren